CA Patent

CA2705318C — Inhibitors of human immunodeficiency virus replication

Assigned to Gilead Sciences Inc · Expires 2013-12-31 · 12y expired

What this patent protects

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

USPTO Abstract

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

Drugs covered by this patent

cabotegravir-sodium (CABOTEGRAVIR SODIUM)

Patent Metadata

Patent number: CA2705318C
Jurisdiction: CA
Classification: —
Expires: 2013-12-31
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.